Regina Nethery to Retire as Vice President of Investor Relations

Tenet Healthcare Corporation (NYSE: THC) announced today that Regina Nethery, Vice President of Investor Relations, has chosen to retire from her position, effective at the end of 2021.

“We are extremely grateful to Regina for her thoughtful, strategic counsel and tremendous contributions to the organization throughout her tenure,” said Dan Cancelmi, Executive Vice President and Chief Financial Officer. “Regina’s recent recognition as one of the best Investor Relations professionals in Institutional Investor’s survey of Wall Street analysts is a testament to her exceptional contributions to the Company. We will miss Regina and wish her the best on her retirement.”

“I am pleased to have had the opportunity to share Tenet’s corporate strategy and its operational and financial progress with investors,” said Nethery. “I look forward to seeing Tenet’s further growth as I enter this next chapter of my life.”

“I echo Dan’s comments and have found Regina’s dedication, resilience and her balance in furthering our transparency to the market to be exceptional,” said Ron Rittenmeyer, Executive Chairman. “We wish her the very best in retirement.”

Tenet is working with Russell Reynolds Associates to conduct a national search for Nethery’s replacement.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.